AAAAAA

   
Results: 1-25 |
Results: 25
Breakthrough of Ac-225 and its radionuclide daughters from an Ac-225/Bi-213 generator: development of new methods, quantitative characterization, andimplications for clinical use
Authors: Ma, DH McDevitt, MR Finn, RD Scheinberg, DA
Citation: Dh. Ma et al., Breakthrough of Ac-225 and its radionuclide daughters from an Ac-225/Bi-213 generator: development of new methods, quantitative characterization, andimplications for clinical use, APPL RAD IS, 55(5), 2001, pp. 667-678
Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals
Authors: Ma, DH McDevitt, MR Finn, RD Scheinberg, DA
Citation: Dh. Ma et al., Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals, APPL RAD IS, 55(4), 2001, pp. 463-470
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
Authors: Soignet, SL Frankel, SR Douer, D Tallman, MS Kantarjian, H Calleja, E Stone, RM Kalaycio, M Scheinberg, DA Steinherz, P Sievers, EL Coutre, S Dahlberg, S Ellison, R Warrell, RP
Citation: Sl. Soignet et al., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J CL ONCOL, 19(18), 2001, pp. 3852-3860
Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia
Authors: Kolbert, KS Hamacher, KA Jurcic, JG Scheinberg, DA Larson, SM Sgouros, G
Citation: Ks. Kolbert et al., Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia, J NUCL MED, 42(1), 2001, pp. 27-32
Tumor therapy with targeted atomic nanogenerators
Authors: McDevitt, MR Ma, DS Lai, LT Simon, J Borchardt, P Frank, RK Wu, K Pellegrini, V Curcio, MJ Miederer, M Bander, NH Scheinberg, DA
Citation: Mr. Mcdevitt et al., Tumor therapy with targeted atomic nanogenerators, SCIENCE, 294(5546), 2001, pp. 1537-1540
Response of LNCaP spheroids after treatment with an alpha-particle emitter(Bi-213)-labeled anti-prostate-specific membrane antigen antibody (J591)
Authors: Ballangrud, AM Yang, WH Charlton, DE McDevitt, MR Hamacher, KA Panageas, KS Ma, DS Bander, NH Scheinberg, DA Sgouros, G
Citation: Am. Ballangrud et al., Response of LNCaP spheroids after treatment with an alpha-particle emitter(Bi-213)-labeled anti-prostate-specific membrane antigen antibody (J591), CANCER RES, 61(5), 2001, pp. 2008-2014
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
Authors: Jurcic, JG Nimer, SD Scheinberg, DA DeBlasio, T Warrell, RP Miller, WH
Citation: Jg. Jurcic et al., Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia, BLOOD, 98(9), 2001, pp. 2651-2656
Finally, able to present ABL
Authors: Scheinberg, DA
Citation: Da. Scheinberg, Finally, able to present ABL, BLOOD, 98(10), 2001, pp. 2885
Speed bumps on the road to antibody therapy
Authors: Scheinberg, DA
Citation: Da. Scheinberg, Speed bumps on the road to antibody therapy, CANCER J, 6(2), 2000, pp. 64-65
Cell surface receptor-targeted therapy of acute myeloid leukemia: A review
Authors: Frankel, AE Sievers, EL Scheinberg, DA
Citation: Ae. Frankel et al., Cell surface receptor-targeted therapy of acute myeloid leukemia: A review, CANC BIO R, 15(5), 2000, pp. 459-476
Monoclonal antibody therapies - a 'constant' threat to cancer
Authors: Houghton, AN Scheinberg, DA
Citation: An. Houghton et Da. Scheinberg, Monoclonal antibody therapies - a 'constant' threat to cancer, NAT MED, 6(4), 2000, pp. 373-374
Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
Authors: Jurcic, JG DeBlasio, T Dumont, L Yao, TJ Scheinberg, DA
Citation: Jg. Jurcic et al., Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia, CLIN CANC R, 6(2), 2000, pp. 372-380
Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches
Authors: Jurcic, JG Cathcart, K Pinilla-Ibarz, J Scheinberg, DA
Citation: Jg. Jurcic et al., Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches, CURR OPIN H, 7(4), 2000, pp. 247-254
Consolidation therapy with high-dose cyclophosphamide improves the qualityof response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy
Authors: Weiss, MA Glenn, M Maslak, P Rahman, Z Noy, A Zelenetz, A Scheinberg, DA Golde, DW
Citation: Ma. Weiss et al., Consolidation therapy with high-dose cyclophosphamide improves the qualityof response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy, LEUKEMIA, 14(9), 2000, pp. 1577-1582
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
Authors: Camacho, LH Soignet, SL Chanel, S Ho, R Heller, G Scheinberg, DA Ellison, R Warrell, RP
Citation: Lh. Camacho et al., Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide, J CL ONCOL, 18(13), 2000, pp. 2620-2625
CML vaccines as a paradigm of the specific immunotherapy of cancer
Authors: Pinilla-Ibarz, J Cathcart, K Scheinberg, DA
Citation: J. Pinilla-ibarz et al., CML vaccines as a paradigm of the specific immunotherapy of cancer, BLOOD REV, 14(2), 2000, pp. 111-120
An alpha-particle emitting antibody ([Bi-213]J591) for radioimmunotherapy of prostate cancer
Authors: McDevitt, MR Barendswaard, E Ma, D Lai, L Curcio, MJ Sgouros, G Ballangrud, AM Yang, WH Finn, RD Pellegrini, V Geerlings, MW Lee, M Brechbiel, MW Bander, NH Cordon-Cardo, C Scheinberg, DA
Citation: Mr. Mcdevitt et al., An alpha-particle emitting antibody ([Bi-213]J591) for radioimmunotherapy of prostate cancer, CANCER RES, 60(21), 2000, pp. 6095-6100
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
Authors: Pinilla-Ibarz, J Cathcart, K Korontsvit, T Soignet, S Bocchia, M Caggiano, J Lai, L Jimenez, J Kolitz, J Scheinberg, DA
Citation: J. Pinilla-ibarz et al., Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses, BLOOD, 95(5), 2000, pp. 1781-1787
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia
Authors: Kossman, SE Scheinberg, DA Jurcic, JG Jimenez, J Caron, PC
Citation: Se. Kossman et al., A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia, CLIN CANC R, 5(10), 1999, pp. 2748-2755
An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation
Authors: McDevitt, MR Finn, RD Sgouros, G Ma, DS Scheinberg, DA
Citation: Mr. Mcdevitt et al., An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation, APPL RAD IS, 50(5), 1999, pp. 895-904
[I-125]Orphanin FQ/nociceptin binding in Raji cells
Authors: Hom, JSH Goldberg, I Mathis, J Pan, YX Brooks, AI Ryan-Moro, J Scheinberg, DA Pasternak, GW
Citation: Jsh. Hom et al., [I-125]Orphanin FQ/nociceptin binding in Raji cells, SYNAPSE, 34(3), 1999, pp. 187-191
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia
Authors: Sgouros, G Ballangrud, AM Jurcic, JG McDevitt, MR Humm, JL Erdi, YE Mehta, BM Finn, RD Larson, SM Scheinberg, DA
Citation: G. Sgouros et al., Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia, J NUCL MED, 40(11), 1999, pp. 1935-1946
Preparation of alpha-emitting Bi-213-labeled antibody constructs for clinical use
Authors: McDevitt, MR Finn, RD Ma, D Larson, SM Scheinberg, DA
Citation: Mr. Mcdevitt et al., Preparation of alpha-emitting Bi-213-labeled antibody constructs for clinical use, J NUCL MED, 40(10), 1999, pp. 1722-1727
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry
Authors: Nikula, TK McDevitt, MR Finn, RD Wu, CC Kozak, RW Garmestani, K Brechbiel, MW Curcio, MJ Pippin, CG Tiffany-Jones, L Geerlings, MW Apostolidis, C Molinet, R Geerlings, MW Gansow, OA Scheinberg, DA
Citation: Tk. Nikula et al., Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry, J NUCL MED, 40(1), 1999, pp. 166-176
Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells
Authors: Weisburg, JH Roepe, PD Dzekunov, S Scheinberg, DA
Citation: Jh. Weisburg et al., Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells, J BIOL CHEM, 274(16), 1999, pp. 10877-10888
Risultati: 1-25 |